期刊
HAEMATOLOGICA
卷 93, 期 2, 页码 287-290出版社
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.11891
关键词
acute lymphoblastic leukemia; Philadelphia chromosome; BCR-ABL; imatinib; karyotype
类别
资金
- Japanese Ministry of Education, Culture, Sports, Science, and Technology
To identify factors associated with relapse-free survival (RFS), 80 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, enrolled in a phase II study of imatinib-combined chemotherapy, were analyzed. The median follow-up of surviving patients was 26.7 months (maximum, 52.5 months). Twenty-eight out of 77 patients who had achieved CR relapsed. The probability of RFS was 50.5% at 2 years. Multivariate analysis revealed that the presence of secondary chromosome aberrations in addition to t(9;22) at diagnosis constitute an independent predictive value for RFS (p=0.027), and increase the risk of treatment failure by 2.8-fold.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据